SCHEMBL1286136

SCHEMBL1286136

NNC(=O)C1=CC(=O)NC1=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.33
ALDH1A1 P00352 5/20 0.33
MPO P05164 2/20 0.33
CYP3A4 P08684 2/20 0.33
BLM P54132 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
P2RX7 Q99572 1/20 0.33
KDM5A P29375 1/20 0.33
GFER P55789 1/20 0.33
PMP22 Q01453 1/20 0.33
HIF1A Q16665 1/20 0.33
MAPT P10636 3/20 0.32
LMNA P02545 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
GAA P10253 2/20 0.32
NSD2 O96028 1/20 0.32
ALPL P05186 1/20 0.32
POLB P06746 1/20 0.32
ALPI P09923 1/20 0.32
ALPG P10696 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6022461 0.76
SCHEMBL347103 0.73 LDHA (0.32) BLMSMN1; SMN2
SCHEMBL11880209 0.71
SCHEMBL9959060 0.67
SCHEMBL11880200 0.67
SCHEMBL27775587 0.65 MAPT (0.32) MAPT
SCHEMBL676346 0.64 NR4A1 (0.35) KDM4EALDH1A1MPOCYP3A4BLM
SCHEMBL8586498 0.63 CYP3A4 (0.46) KDM4EALDH1A1CYP3A4SMN1; SMN2MAPT
SCHEMBL2687724 0.62 P2RX7 (0.38) KDM4EALDH1A1MPOCYP3A4BLM
SCHEMBL11128096 0.62 PEPD (0.33) ALDH1A1GFERMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230347016-A1 VALVE MATERIAL WITH LONG-ACTING ANTITHROMBOSIS PROPERTY AND PREPARATION METHOD THEREFOR VENUS MEDTECH (HANGZHOU) INC. (CN) 2023-11-02 US claimed
EP-4137168-A1 VALVE MATERIAL HAVING LONG-ACTING ANTITHROMBOSIS PROPERTY AND PREPARATION METHOD THEREFOR Venus MedTech (HangZhou), Inc. (CN) 2023-02-22 EP claimed
CN-112386695-B Chitosan-based nano prodrug carrying indocyanine green and platinum drugs and preparation method thereof 西安交通大学 2021-11-19 CN claimed
CN-112480289-B Core-shell structure type chitosan-based nano prodrug carrying doxorubicin and platinum drugs together, and preparation method and application thereof 西安交通大学 2021-09-07 CN claimed
CN-111658825-B Valve material with long-acting antithrombotic performance and preparation method thereof 四川大学 2021-03-30 CN claimed
CN-112480289-A Core-shell structure type chitosan-based nano prodrug carrying doxorubicin and platinum drugs together, and preparation method and application thereof 西安交通大学 2021-03-12 CN claimed
CN-112386695-A Chitosan-based nano prodrug carrying indocyanine green and platinum drugs and preparation method thereof 西安交通大学 2021-02-23 CN claimed
US-7667048-B2 Green and orange fluorescent labels and their uses ARIES ASSOCIATES, INC. (US) 2010-02-23 US claimed
US-20080261235-A1 Novel Green and Orange Fluorescent Labels and Their Uses BHATT RAM 2008-10-23 US claimed
EP-1303635-B1 METHOD FOR THE SELECTIVE SURVIVAL OR SELECTIVE GROWTH OF A TARGET CELL BY THE USE OF A CONJUGATE, ITS USE IN THE THERAPEUTICS AND/OR DIAGNOSTICS UNIV CATHOLIQUE LOUVAIN (BE) 2007-02-21 EP claimed
EP-1546673-A4 NOVEL GREEN AND ORANGE FLUORESCENT LABELS AND THEIR USES CHROMAGEN INC (US) 2006-08-09 EP claimed
US-6969593-B2 Method for the selective survival or selective growth of a target cell by the use of a conjugate, its use in therapeutics and/or diagnostics and the preparation of said conjugate UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2005-11-29 US claimed
EP-1546673-A2 NOVEL GREEN AND ORANGE FLUORESCENT LABELS AND THEIR USES CHROMAGEN, INC. (US) 2005-06-29 EP claimed
US-20040106806-A1 Novel green and orange fluorescent labels and their uses ARIES ASSOCIATES, INC. 2004-06-03 US claimed
WO-2004027388-A2 NOVEL GREEN AND ORANGE FLUORESCENT LABELS AND THEIR USES CHROMAGEN, INC. (US) 2004-04-01 WO claimed
US-20030099658-A1 Method for the selective survival or selective growth of a target cell by the use of a conjugate, its use in therapeutics and/or diagnostics and the prepration of said conjugate UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2003-05-29 US claimed
US-20230347016-A1 VALVE MATERIAL WITH LONG-ACTING ANTITHROMBOSIS PROPERTY AND PREPARATION METHOD THEREFOR VENUS MEDTECH (HANGZHOU) INC. (CN) 2023-11-02 US disclosed
CN-110049776-B Immunogenic polysaccharide comprising conjugated protein derived from group B Streptococcus GBS polysaccharide 辉瑞大药厂 2023-09-08 CN disclosed
US-5066789-A Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages NEORX CORPORATION (US) 1991-11-19 US disclosed
WO-1990003401-A1 TARGETING SUBSTANCE-DIAGNOSTIC/THERAPEUTIC AGENT CONJUGATES HAVING SCHIFF BASE LINKAGES NEORX CORPORATION (US) 1990-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106806-A1 Novel green and orange fluorescent labels and their uses CD69, ANXA5, ANXA6 KDM4E 3408/4885ALDH1A1 2125/4885MPO 2795/4885
US-20080261235-A1 Novel Green and Orange Fluorescent Labels and Their Uses CD69, ANXA6, ANXA5 KDM4E 3665/4885ALDH1A1 1993/4885MPO 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.